Regeneron Pharmaceuticals (REGN) Getting Favorable News Coverage, Study Finds

Media headlines about Regeneron Pharmaceuticals (NASDAQ:REGN) have been trending positive recently, AlphaOne Sentiment Analysis reports. AlphaOne, a service of Accern, identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 0.26 on AlphaOne’s scale. AlphaOne also gave media coverage about the biopharmaceutical company an impact score of 78 out of 100, meaning that recent press coverage is likely to have an impact on the stock’s share price in the near term.

Here are some of the news headlines that may have impacted AlphaOne Sentiment’s analysis:

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Shares of Regeneron Pharmaceuticals (NASDAQ REGN) traded down 2.04% during midday trading on Friday, hitting $459.91. 1,658,740 shares of the company traded hands. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $489.00. The stock has a market capitalization of $48.55 billion, a P/E ratio of 55.67 and a beta of 1.53. The stock’s 50-day moving average is $450.98 and its 200 day moving average is $392.16. Regeneron Pharmaceuticals also saw some unusual options trading activity on Wednesday. Stock traders acquired 1,049 call options on the stock. This represents an increase of approximately 368% compared to the average daily volume of 224 call options.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.50 by $0.42. The company had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The business’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.57 earnings per share. On average, analysts expect that Regeneron Pharmaceuticals will post $12.66 earnings per share for the current year.

Several research analysts have commented on REGN shares. Vetr upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $475.44 target price for the company in a research report on Wednesday, March 15th. BMO Capital Markets restated a “hold” rating and issued a $412.00 target price (up previously from $408.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 28th. Leerink Swann restated an “outperform” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, March 20th. Canaccord Genuity upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the stock from $375.00 to $484.00 in a research report on Friday, May 5th. Finally, Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 price objective for the company in a report on Thursday, April 27th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have assigned a buy rating to the stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and an average target price of $434.17.

WARNING: “Regeneron Pharmaceuticals (REGN) Getting Favorable News Coverage, Study Finds” was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.wkrb13.com/markets/2230831/regeneron-pharmaceuticals-regn-getting-favorable-news-coverage-study-finds.html.

In other news, Director Michael S. Brown sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 29th. The shares were sold at an average price of $400.00, for a total value of $400,000.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $400,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Neil Stahl sold 8,567 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $468.45, for a total transaction of $4,013,211.15. Following the completion of the transaction, the executive vice president now owns 44,245 shares of the company’s stock, valued at approximately $20,726,570.25. The disclosure for this sale can be found here. Insiders sold 25,674 shares of company stock valued at $11,852,498 in the last quarter. Corporate insiders own 10.40% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230831/regeneron-pharmaceuticals-regn-getting-favorable-news-coverage-study-finds.html

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.